Who owns AgomAb Therapeutics NV?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of AGMB from SEC Form 13F filings across 34 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 34 institutions disclosed 26.0M shares of AgomAb Therapeutics NV worth $337.0M — about 76% of shares outstanding; the largest disclosed holder is EQT Fund Management S.a r.l.. Source: SEC Form 13F filings, parsed by EvidInvest.
34
13F holders
$337.0M
value, 2026 filers
76%
of shares outstanding (26.0M sh)
9
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of AGMB's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | EQT Fund Management S.a r.l. | 5.1M | $66.7M | 7.7% | 15% | 0.0% |
| 2 | Sanofi | 2.8M | $36.1M | 6.8% | 8.1% | 0.0% |
| 3 | Redmile Group, LLC | 2.7M | $35.5M | 2.4% | 8% | +1649.7% |
| 4 | Cormorant Asset Management, LP | 2.5M | $32.0M | 1.6% | 7.2% | 0.0% |
| 5 | TCG Crossover Management, LLC | 2.1M | $26.7M | 0.6% | 6% | 0.0% |
| 6 | FEDERATED HERMES, INC. | 1.6M | $21.0M | 0.0% | 4.7% | 0.0% |
| 7 | Nantahala Capital Management, LLC | 1.6M | $20.4M | 0.7% | 4.6% | +30.7% |
| 8 | Casdin Capital, LLC | 1.6M | $20.1M | 1.0% | 4.5% | 0.0% |
| 9 | ANDERA PARTNERS | 1.5M | $20.0M | 9.7% | 4.5% | 0.0% |
| 10 | FMR LLC | 1.5M | $18.9M | 0.0% | 4.3% | 0.0% |
| 11 | Aberdeen Group plc | 846,695 | $11.0M | 0.0% | 2.5% | +19.6% |
| 12 | SAMSARA BIOCAPITAL, LLC | 600,000 | $7.8M | 0.6% | 1.8% | 0.0% |
| 13 | PERCEPTIVE ADVISORS LLC | 600,000 | $7.8M | 0.1% | 1.8% | 0.0% |
| 14 | Siren, L.L.C. | 411,250 | $5.3M | 0.1% | 1.2% | 0.0% |
| 15 | ORBIMED ADVISORS LLCNEW | 192,740 | $2.5M | 0.0% | 0.6% | new |
| 16 | Pfizer Inc | 75,000 | $1.0M | 0.6% | 0.2% | 0.0% |
| 17 | ALPS ADVISORS INCNEW | 49,984 | $648,792 | 0.0% | 0.1% | new |
| 18 | Bellevue Group AG | 49,248 | $639,239 | 0.0% | 0.1% | -1.5% |
| 19 | SEVEN GRAND MANAGERS, LLC | 47,600 | $617,848 | 0.0% | 0.1% | -76.2% |
| 20 | SECTORAL ASSET MANAGEMENT INC | 43,500 | $564,630 | 0.4% | 0.1% | 0.0% |
| 21 | Burkehill Global Management, LP | 35,000 | $454,300 | 0.0% | 0.1% | 0.0% |
| 22 | Quadrature Capital LtdNEW | 20,461 | $265,584 | 0.0% | 0.1% | new |
| 23 | TWO SIGMA INVESTMENTS, LP | 18,072 | $234,575 | 0.0% | 0.1% | +26.9% |
| 24 | HRT FINANCIAL LP | 17,075 | $221,000 | 0.0% | 0% | -28.0% |
| 25 | GOLDMAN SACHS GROUP INC | 11,800 | $153,164 | 0.0% | 0% | -67.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.